Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):


	Year Ended December 31,
	2025		2024		2023
Numerator:
Net loss	$	(31,080)	$	(22,705)	$	(25,966)
Less: Net loss attributable to noncontrolling interests	(4,106)		(4,243)		(5,716)
Net loss attributable to vTv Therapeutics Inc.	(26,974)		(18,462)		(20,250)

Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted	$	(26,974)	$	(18,462)	$	(20,250)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)	8,423,632		5,771,052		2,084,973
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted	$	(3.20)	$	(3.20)	$	(9.71)


			(1)			The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the year ended December 31, 2025 and 2024.

Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:


	Year Ended December 31,
	2025	2024	2023
Class B common stock (1)	241	577,349	577,349
Common stock options granted under the Plan	1,017,620	705,593	249,247
Common stock warrants	5,292,892	70,639	76,545
Total	6,310,753	1,353,581	903,141

________________________________________________

(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

vTv Therapeutics Inc. 10-K